Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

Incyte's experimental skin disease drug met the main goal of two separate late-stage trials, but data showed that it was not as effective as in its prior studies, sending the drugmaker's shares down ...

Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...

Incyte's experimental skin disease drug met the main goal of two separate late-stage trials, the company said on Monday, but its shares declined 11% as the drug significantly underperformed prior ...

The Wilmington, Del., biopharmaceutical company said the study data support planned worldwide regulatory submissions for povorcitinib for the treatment of hidradenitis suppurativa, which can lead to ...

Incyte's povorcitinib met key Phase 3 trial endpoints in hidradenitis suppurativa, showing significant clinical response and a well-tolerated safety profile.

New research from the University of Otago, Christchurch—Ōtakau Whakaihu Waka, Ōtautahi, has exposed the large number of ...

American Society of Regional Anesthesia and Pain Medicine guidelines highlight SSI prevention in regional anesthesia and ...

Prosecutors won't say why they withdrew their intent to seek the death penalty against a couple accused of murdering their ...

He says the results highlight the stigma, discrimination and cost barriers experienced by injecting drug users in New Zealand ... including abscesses, septicemia, thrombosis, endocarditis ...

For example, researchers at Thomas Jefferson University in Philadelphia found that people with xylazine-associated wounds are often denied admittance to detox and rehabilitation programs until their ...